Short-term effects of dapagliflozin on biomarkers of bone and mineral metabolism in patients with diabetic kidney disease: A prospective observational study Tugba Islek, Safak Mirioglu, Meltem Gursu, Rumeyza Kazancioglu, Metin Demirel, Sahabettin Selek, Omer Celal Elcioglu

Evaluation of clinical events and costs associated with the addition of dapagliflozin to chronic kidney disease treatment: Cost offset analysis Juan Francisco Navarro-González, Alberto Ortiz, Ana Cebrián Cuenca, Lluís Segú, Belén Pimentel, Unai Aranda, Blanca Lopez-Chicheri, Margarita Capel, Elisenda Pomares Mallol, Christian Caudron, Juan José García Sánchez, Roberto Alcázar Arroyo

The correlation between sclerostin and bone mineral density in renal transplant recipients Melahat Coban, Sarper Okten